| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5674872 | SANDOZ | Treatment of ovarian cancer |
Oct, 2014
(9 years ago) | |
|
US5674872 (Pediatric) | SANDOZ | Treatment of ovarian cancer |
Apr, 2015
(9 years ago) | |
| US8158645 | SANDOZ | Compound, corresponding compositions, preparation and/or treatment methods |
Dec, 2024
(7 months from now) | |
Hycamtin is owned by Sandoz.
Hycamtin contains Topotecan Hydrochloride.
Hycamtin has a total of 3 drug patents out of which 2 drug patents have expired.
Expired drug patents of Hycamtin are:
- US5674872
- US5674872*PED
Hycamtin was authorised for market use on 28 May, 1996.
Hycamtin is available in capsule;oral, injectable;injection dosage forms.
Hycamtin can be used as treatment of metastatic carcinoma of the ovary after failure of initial or subsequent chemotherapy.
The generics of Hycamtin are possible to be released after 10 December, 2024.
Drugs and Companies using TOPOTECAN HYDROCHLORIDE ingredient
Market Authorisation Date: 28 May, 1996
Treatment: Treatment of metastatic carcinoma of the ovary after failure of initial or subsequent chemotherapy
Dosage: INJECTABLE;INJECTION; CAPSULE;ORAL
HYCAMTIN family patents
